Clinical Trial Update: The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating low-dose rituximab plus ATRA for steroid-resistant or relapsed immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• ATRA (all-trans retinoic acid)
• Rituximab (rituximab)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN